Global X Genomics & Biotechnology ETF (GNOM) to Issue Dividend of $0.59 on January 7th

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) declared a dividend on Monday, December 29th. Shareholders of record on Tuesday, December 30th will be paid a dividend of 0.5912 per share on Wednesday, January 7th. This represents a yield of 259.0%. The ex-dividend date of this dividend is Tuesday, December 30th.

Global X Genomics & Biotechnology ETF Stock Performance

NASDAQ GNOM opened at $45.51 on Wednesday. The company has a market capitalization of $55.52 million, a P/E ratio of -19.43 and a beta of 1.22. Global X Genomics & Biotechnology ETF has a one year low of $27.20 and a one year high of $48.09. The stock has a 50 day moving average price of $45.18 and a 200-day moving average price of $39.72.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several institutional investors and hedge funds have recently bought and sold shares of GNOM. HighTower Advisors LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 16.7% during the 1st quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock worth $121,000 after purchasing an additional 2,184 shares during the period. Jane Street Group LLC raised its holdings in Global X Genomics & Biotechnology ETF by 7.7% in the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after purchasing an additional 10,308 shares during the period. Oxinas Partners Wealth Management LLC boosted its position in Global X Genomics & Biotechnology ETF by 12.1% during the second quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock worth $137,000 after purchasing an additional 1,751 shares in the last quarter. Halbert Hargrove Global Advisors LLC grew its holdings in Global X Genomics & Biotechnology ETF by 182.4% in the second quarter. Halbert Hargrove Global Advisors LLC now owns 13,685 shares of the company’s stock valued at $115,000 after purchasing an additional 8,839 shares during the period. Finally, Insight Advisors LLC PA lifted its position in shares of Global X Genomics & Biotechnology ETF by 47.9% during the 2nd quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock valued at $503,000 after buying an additional 19,319 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.